Statin use and its potential therapeutic role in esophageal cancer: a systematic review and meta-analysis

References

• Domper Arnal MJ, Ferrandez Arenas A, Lanas Arbeloa A. Esophageal cancer: risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol. 2015;21(26):7933–7943. doi:10.3748/wjg.v21.i26.793326185366
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. doi:10.3322/caac.2138728055103
   PubMed Web of Science ®Google Scholar
• Lagergren J, Smyth E, Cunningham D, Lagergren P. Oesophageal cancer. Lancet. 2017;390(10110):2383–2396. doi:10.1016/S0140-6736(17)31462-928648400
   PubMed Web of Science ®Google Scholar
• Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nature Rev Drug Discovery. 2004;3(8):673–683. doi:10.1038/nrd146815286734
   PubMed Web of Science ®Google Scholar
• Shim JS, Liu JO. Recent advances in drug repositioning for the discovery of new anticancer drugs. Int J Biol Sci. 2014;10(7):654–663. doi:10.7150/ijbs.922425013375
   PubMed Web of Science ®Google Scholar
• Stadtmauer EA. Tailoring initial treatment for newly diagnosed, transplantation-eligible multiple myeloma. Oncology. 2010;24(3 Suppl 2):7–13. 20518365
   PubMed Web of Science ®Google Scholar
• Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol. 2004;22(13):2532–2539. doi:10.1200/JCO.2004.05.07415226321
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376(9754):1741–1750. doi:10.1016/S0140-6736(10)61543-720970847
   PubMed Web of Science ®Google Scholar
• Nevadunsky NS, Van Arsdale A, Strickler HD, et al. Metformin use and endometrial cancer survival. Gynecol Oncol. 2014;132(1):236–240. doi:10.1016/j.ygyno.2013.10.02624189334
   PubMed Web of Science ®Google Scholar
• Sirtori CR. The pharmacology of statins. Pharmacol Res. 2014;88:3–11. doi:10.1016/j.phrs.2014.03.00224657242
   PubMed Web of Science ®Google Scholar
• Miraglia E, Hogberg J, Stenius U. Statins exhibit anticancer effects through modifications of the pAkt signaling pathway. Int J Oncol. 2012;40(3):867–875. doi:10.3892/ijo.2011.122321994073
   PubMed Web of Science ®Google Scholar
• Pisanti S, Picardi P, Ciaglia E, D’Alessandro A, Bifulco M. Novel prospects of statins as therapeutic agents in cancer. Pharmacol Res. 2014;88:84–98. doi:10.1016/j.phrs.2014.06.01325009097
   PubMed Web of Science ®Google Scholar
• Ye F, Zhang GH, Guan BX, Xu XC. Suppression of esophageal cancer cell growth using curcumin, (-)-epigallocatechin-3-gallate and lovastatin. World J Gastroenterol. 2012;18(2):126–135. doi:10.3748/wjg.v18.i2.12622253518
   PubMed Web of Science ®Google Scholar
• Sadaria MR, Reppert AE, Yu JA, et al. Statin therapy attenuates growth and malignant potential of human esophageal adenocarcinoma cells. J Thorac Cardiovasc Surg. 2011;142(5):1152–1160. doi:10.1016/j.jtcvs.2011.08.00422014341
   PubMed Web of Science ®Google Scholar
• Singh S, Singh AG, Singh PP, Murad MH, Iyer PG. Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11(6):620–629. doi:10.1016/j.cgh.2012.12.03623357487
   PubMed Web of Science ®Google Scholar
• Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2016;354:i4086. 27444514
   PubMedGoogle Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–605. doi:10.1007/s10654-010-9491-z20652370
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188. 3802833
   PubMedGoogle Scholar
• Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560. doi:10.1136/bmj.327.7414.55712958120
   PubMed Web of Science ®Google Scholar
• Ioannidis JP, Patsopoulos NA, Evangelou E. Uncertainty in heterogeneity estimates in meta-analyses. BMJ. 2007;335(7626):914–916. doi:10.1136/bmj.39343.408449.8017974687
   PubMed Web of Science ®Google Scholar
• Melsen WG, Bootsma MC, Rovers MM, Bonten MJ. The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses. Clin Microbiol Infect. 2014;20(2):123–129. doi:10.1111/1469-0691.1249424320992
   PubMed Web of Science ®Google Scholar
• Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–1101. 7786990
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634. 9310563
   PubMed Web of Science ®Google Scholar
• Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. BMJ. 2011;342:d549. doi:10.1136/bmj.d54921310794
   PubMed Web of Science ®Google Scholar
• Nguyen T, Khan A, Liu Y, El-Serag HB, Thrift AP. The association between statin use after diagnosis and mortality risk in patients with esophageal cancer: a retrospective cohort study of United States veterans. Am J Gastroenterol. 2018. doi:10.1038/s41395-018-0169-6
   Google Scholar
• Nimako GK, Wintrob ZA, Sulik DA, Donato JL, Ceacareanu AC. Synergistic benefit of statin and metformin in gastrointestinal malignancies. J Pharm Pract. 2017;30(2):185–194. doi:10.1177/089719001562725526811340
   PubMedGoogle Scholar
• Cardwell CR, Spence AD, Hughes CM, Murray LJ. Statin use after esophageal cancer diagnosis and survival: a population based cohort study. Cancer Epidemiol. 2017;48:124–130. doi:10.1016/j.canep.2017.04.01528486205
   PubMed Web of Science ®Google Scholar
• Alexandre L, Clark AB, Bhutta HY, Chan SS, Lewis MP, Hart AR. Association between statin use after diagnosis of esophageal cancer and survival: a population-based cohort study. Gastroenterology. 2016;150(4):854–865.e851;quiz e816–e857. doi:10.1053/j.gastro.2015.12.039
   PubMed Web of Science ®Google Scholar
• Lacroix O, Couttenier A, Vaes E, Cardwell CR, De Schutter H, Robert A. Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study. Cancer Causes Control. 2019. doi:10.1007/s10552-019-01149-3
   PubMed Web of Science ®Google Scholar
• Ogunwobi OO, Beales IL. Statins inhibit proliferation and induce apoptosis in Barrett’s esophageal adenocarcinoma cells. Am J Gastroenterol. 2008;103(4):825–837. doi:10.1111/j.1572-0241.2007.01773.x18371146
   PubMed Web of Science ®Google Scholar
• Thomas T, Loke Y, Beales ILP. Systematic review and meta-analysis: use of statins is associated with a reduced incidence of oesophageal adenocarcinoma. J Gastrointest Cancer. 2018;49(4):442–454. doi: 10.1007/s12029-017-9983-028691139
   PubMed Web of Science ®Google Scholar
• Mei Z, Liang M, Li L, Zhang Y, Wang Q, Yang W. Effects of statins on cancer mortality and progression: a systematic review and meta-analysis of 95 cohorts including 1,111,407 individuals. Int J Cancer. 2017;140(5):1068–1081. doi:10.1002/ijc.3052627859151
   PubMed Web of Science ®Google Scholar
• Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med. 2012;367(19):1792–1802. doi:10.1056/NEJMoa120173523134381
   PubMed Web of Science ®Google Scholar